Overview

Pegvisomant And Sandostatin LAR Combination Study

Status:
Completed

Trial end date:
2006-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the safety and tolerability of combination therapy with Sandostatin LAR plus Pegvisomant to that of Sandostatin LAR alone or Pegvisomant alone.

Phase:

Phase 4

Details

Lead Sponsor:

Pfizer

Treatments:

Octreotide